Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 1997

View Archived Issues

UCSF and Stanford develop mouse model of basal cell carcinoma

Senetek seeks European approval of erectile dysfunction therapy

Preliminary clinical results for Lexirin

Maxim starts clinical trial of Maxamine in hepatitis C

Chiron and Biomira enter partnership for Theratope cancer vaccine

ECE inhibitors from Santen

Novo Nordisk describes heterocyclic compounds for neurogenic pain/inflammation

Pharmacia & Upjohn prepares new antibacterial agents

Compounds with dual antiinflammatory/antioxidant activity from Alcon

Genentech enters into agreement for embryonic stem cell renewal factor

Highly effective anthrapyrazole described by Boehringer Mannheim and U. of Vermont

GeneMedicine reports development of a negative GeneSwitch

Company Profile: Kinetek Pharmaceuticals

Zeneca and University of California to codevelop drugs for immunosuppression

MedImmune reports further clinical results for MEDI-493

Novel antitumor gene therapy under development at Oxford BioMedica

Tumor regression reported for StressGen's stress gene therapy

Medarex acquires GenPharm

Neose Technologies initiates phase II trials with antiulcer drug

Kissei licenses antidiabetic agent to Purdue

Tanabe licenses T-0632 to Zeria

Taisho to develop Tanabe MAO-A inhibitor

Mibefradil evaluated for impact on mortality in large CHF trial

FDA decision on generic Premarin

CSID enzyme replacement therapy submitted for approval

FDA requests additional data to support Gilead's NDA for HSV treatment

Baxter files European marketing application for HemAssist

Pall and LifeTECH will not pursue strategic alliance

Oxi-104 to enter clinic

AMBI to submit IND for nisin

FDA advisory panel denies approval for Genzyme's Sepracoat

BMS and Sanofi seek U.S. and European approval for clopidogrel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...